Welcome to our dedicated page for Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares stock.
Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) is at the forefront of developing innovative respiratory support technology as an alternative to invasive mechanical ventilation. The company's flagship product, INSPIRA ART100, is a breakthrough in Augmented Respiration Technology designed to maintain optimal oxygen levels in patients without the need for intubation and sedation. This technology is particularly significant in the treatment of respiratory failure and offers a less invasive option compared to traditional mechanical ventilation.
Inspira Technologies operates in various regions, including North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The company is involved in the research, development, manufacture, and marketing of proprietary respiratory care devices, aiming to transform the landscape of acute and neonatal care.
Recently, Inspira Technologies has announced several key developments:
- April 3, 2024: Commencement of a program to explore the use of the INSPIRA ART100 Device for an artificial womb for neonates requiring vital respiratory support.
- April 10, 2024: Collaborative development with Ennocure MedTech Ltd. on bio-electronic treatment to prevent bloodstream infections in ICU patients, showcasing a 100% reduction in bacterial growth within 24 hours in an in vitro study.
- April 16, 2024: Signing of a collaboration term sheet with Beilinson Hospital for the evaluation of the INSPIRA ART100 device in organ transplant procedures.
- April 25, 2024: Receiving CSA Certification of Compliance to U.S. standards for the INSPIRA ART100 device.
- May 2, 2024: Initiation of the production of the INSPIRA ART100 medical device by a leading technology company.
- May 28, 2024: Notification of 510(k) class II clearance from the U.S. FDA for the INSPIRA ART100.
Inspira's products are designed not only to enhance patient outcomes but also to reduce the costs and complications associated with traditional respiratory support methods. The INSPIRA ART100 system has received FDA clearance, marking a pivotal moment in the company's history. Other products in the pipeline, including the INSPIRA ART (Gen 2) and HYLA™ blood sensor, are poised to further revolutionize respiratory care once approved.
Inspira Technologies (NASDAQ: IINN) announces an upcoming live investor webinar and Q&A session scheduled for November 11, 2024, at 4:15 p.m. EST. The event, hosted by RedChip Companies, will feature company President Joe Hayon discussing innovative life support technology developments. The presentation will focus on their technology designed to monitor and improve declining blood oxygen saturation levels without mechanical ventilation, potentially disrupting the $19 billion mechanical ventilation market. Investors can register for free and submit questions in advance or during the event.
Inspira Technologies (Nasdaq: IINN) has signed a distribution agreement with Glo-Med Networks to serve as its primary distributor in the United States. The agreement establishes a Florida-based distribution facility that will support the deployment of the INSPIRA ART100, which is FDA 510(k)-cleared for Cardiopulmonary Bypass procedures. The facility will provide customer support and after-market services through a partnership with Med-Stat Consulting Services. This strategic move aims to enhance operational efficiency for the planned 2024 deployment of the ART100 and future products. The company's flagship product, INSPIRA ART, targets a potential $19 billion market opportunity, aiming to serve 20 million acute respiratory failure patients annually.
Inspira Technologies (Nasdaq: IINN) has announced a partnership with Glo-Med Networks as its primary U.S. distributor for the INSPIRA ART100 device, which is FDA 510(k)-cleared for Cardiopulmonary Bypass procedures. The distribution facility, located in Florida, will support deployment and maintenance of the system, with Med-Stat Consulting Services providing certified after-market services.
The company's proprietary INSPIRA ART device aims to revolutionize life support for acute respiratory failure patients, targeting a potential $19 billion market opportunity with 20 million annual patients. The technology is designed to monitor and elevate declining blood saturation levels without requiring a mechanical ventilator, with planned deployment beginning in 2024.
Inspira Technologies (Nasdaq: IINN) has announced the development of a new disposable kit for the perfusion market. This innovation is part of Inspira's strategy to generate recurring revenues and potentially tap into the $1 billion perfusion systems market. The single-use kit is designed to identify and alert users on performance changes during operation and treatment, aiming to enhance product safety and patient protection.
The disposable kit will be subject to an FDA clearance application and is expected to be offered to hospitals using the INSPIRA ART100 system. The ART100 system received FDA 510(k) clearance for Cardiopulmonary Bypass procedures in May 2024 and Israeli certification for extra-corporeal membrane oxygenation and cardiopulmonary bypass procedures in July 2024. The first manufactured devices are expected to be deployed in the U.S. by the end of 2024.
Inspira™ Technologies OXY B.H.N. (Nasdaq: IINN, IINNW) is set to showcase its latest innovations at the 34th Annual Extracorporeal Life Support Organization (ELSO) Conference in Detroit, Michigan, from September 29-30, 2024. The company will present its FDA-cleared INSPIRA™ ART100 system, which is ready for deployment in the U.S. market.
Attendees will have the opportunity to experience interactive demonstrations and presentations of Inspira's technologies. The company's U.S. sales team, led by chief distributor Glo-Med Networks Inc., will be present at booth #18 to discuss the potential impact of these innovations on patient care. Key personnel, including VP of Product Tomer Carmeli, Medical Director Dr. Dekel Stavi, and CTO Dr. Daniella Yeheskely-Hayon, will be available to address questions and showcase the INSPIRA™ ART100 system's features and advantages.
Inspira™ Technologies (Nasdaq: IINN) has secured a second U.S. Patent approval for its VORTX™ orbiting blood oxygenation delivery system, a core technology of the INSPIRA™ ART device. This brings the total novel claims for the core technology to 32. The VORTX™ system aims to oxygenate blood without fiber membranes, potentially reducing blood damage and costs compared to current technologies.
The INSPIRA™ ART device targets the $19 billion mechanical ventilation market, offering a potential alternative for the 20 million ICU patients with respiratory failure annually. It aims to maintain stable oxygen saturation levels without ventilators, allowing patients to remain awake during treatment.
Inspira™ Technologies has developed Augmented Respiration Technology (INSPIRA™ ART) with adaptive blood monitoring. The INSPIRA™ ART100 system has obtained FDA 510(k) clearance for Cardiopulmonary Bypass procedures and Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.
Inspira Technologies (Nasdaq: IINN) has announced plans to report clinical results for its HYLA™ blood sensor in Q4 2024. The clip-on sensor aims to alert physicians of changes in a patient's condition without intermittent blood samples, targeting a potential $2.5 billion Point of Care testing and Arterial Blood Gas analyzer market. Inspira is expanding its blood testing facilities to accelerate HYLA™ development, with a 510(k) submission to the FDA planned for early 2025.
The company's broader strategy involves transforming respiratory and life-support sectors, addressing an estimated $59 billion annual market opportunity. Inspira plans to deploy its FDA-cleared INSPIRA™ ART100 system in top U.S. and Israeli hospitals. The company is also developing additional products, including the INSPIRA™ ART (Gen 2) and INSPIRA™ Cardi-ART, focusing on innovative oxygenation and blood monitoring technologies.
Inspira Technologies OXY B.H.N. (IINN) has announced the FDA listing of its INSPIRA™ CART, a medical cart designed for use with the INSPIRA™ ART100 system. This Class I Medical Device, 510(K) Exempt, is intended for use in operating rooms during Cardiopulmonary Bypass procedures. The company aims to streamline healthcare delivery and transform the ART100 system into a mobile workstation.
Inspira is developing novel life support-extending technologies, targeting a combined market opportunity of approximately $59 billion annually. The company's product pipeline includes the HYLA™ blood sensor, INSPIRA™ Cardi-ART, and INSPIRA™ ART (Gen 2). These technologies are designed to monitor blood parameters, support cardiac arrest patients, and provide adaptive blood oxygenation, respectively.
Inspira Technologies (Nasdaq: IINN) has announced that a leading medical technology company approached them to evaluate the operation of their key product in combination with the INSPIRA™ ART100 system. The evaluation, conducted by Inspira researchers, showed that test results exceeded 100% of the standard value for gas transfer at maximum flow when integrated with the ART100 system.
The tests were performed in Inspira's advanced laboratory, simulating oxygen-deficient and carbon dioxide-rich blood conditions. The successful results demonstrate the power and versatility of the INSPIRA™ ART100 system in various technology settings. Inspira believes this validates the system's compatibility and performance with key products of a leading medical technology company, potentially leading to meaningful business development activities.
Inspira Technologies (Nasdaq: IINN) has introduced the INSPIRA Cardi-ART, a portable modular device designed to provide oxygen to the brain during cardiac arrest. This innovation targets the $39.8 billion global cardiac arrest market, expanding Inspira's potential market to approximately $58.8 billion. The device aims to improve survival rates for cardiac arrest patients, particularly outside hospitals where the mortality rate is about 90%.
Key features of the INSPIRA Cardi-ART include:
- Fast emergency response during CPR
- Rapid cannulation and oxygenated blood delivery
- Monitoring of vital parameters using HYLA blood sensor technology
- Hemodynamic support in case of cardiac failure
Inspira plans to submit the device for FDA regulatory approval as early as 2026, pending the final regulatory pathway.
FAQ
What is the current stock price of Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares (IINN)?
What is the market cap of Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares (IINN)?
What does Inspira Technologies do?
What is the INSPIRA ART100?
What regions does Inspira Technologies operate in?
What recent programs has Inspira Technologies announced?
Who are some of Inspira Technologies' partners?
Has the INSPIRA ART100 received regulatory approval?
What makes the INSPIRA ART100 different from traditional mechanical ventilation?
What is the significance of the CSA Certification of Compliance?
What is the financial impact of mechanical ventilation in the U.S.?
Where can I find more information about Inspira Technologies?
